Click here to get full coverage on Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) - The National Law Review

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA)  The National Law Review

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) - The National Law Review

Click here to get full coverage on A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility - simplywall.st

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility  simplywall.st

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility - simplywall.st

Click here to get full coverage on NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - Yahoo Finance

NTLA Stock Rises 20% in 3 Months: Here's What You Should Know  Yahoo Finance

NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM  Intellia Therapeutics

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics

Click here to get full coverage on 13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan

13 new Intellia employees get 67,150 stock units over 3 years  Stock Titan

13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan

Click here to get full coverage on Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Intellia Therapeutics

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026  Intellia Therapeutics

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Intellia Therapeutics

Click here to get full coverage on A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance

A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound  Yahoo Finance

A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN  Intellia Therapeutics

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics

Click here to get full coverage on How The Narrative On Intellia Therapeutics (NTLA) Is Shifting After MAGNITUDE Hold Resolution - Yahoo Finance

How The Narrative On Intellia Therapeutics (NTLA) Is Shifting After MAGNITUDE Hold Resolution  Yahoo Finance

How The Narrative On Intellia Therapeutics (NTLA) Is Shifting After MAGNITUDE Hold Resolution - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates  Intellia Therapeutics

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)  Intellia Therapeutics

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Click here to get full coverage on H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted - Yahoo Finance

H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted  Yahoo Finance

H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates  Intellia Therapeutics

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial  Yahoo Finance

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy  Intellia Therapeutics

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Click here to get full coverage on Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results - Yahoo Finance

Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results  Yahoo Finance

Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema  Intellia Therapeutics

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - Intellia Therapeutics

Click here to get full coverage on Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals - Yahoo Finance

Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals  Yahoo Finance

Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals - Yahoo Finance

Click here to get full coverage on NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Yahoo Finance

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold  Yahoo Finance

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates  Intellia Therapeutics

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Click here to get full coverage on We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?  Yahoo Finance

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Momentum And Pipeline Expectations  Yahoo Finance

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance

Click here to get full coverage on Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Yahoo Finance

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal  Yahoo Finance

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Yahoo Finance

Click here to get full coverage on Reporter’s Notebook: Is Intellia’s Patient Death the Nail in the Coffin for Cas9? - Inside Precision Medicine

Reporter’s Notebook: Is Intellia’s Patient Death the Nail in the Coffin for Cas9?  Inside Precision Medicine

Reporter’s Notebook: Is Intellia’s Patient Death the Nail in the Coffin for Cas9? - Inside Precision Medicine

Click here to get full coverage on Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade - simplywall.st

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade  simplywall.st

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade - simplywall.st

Click here to get full coverage on Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress  Intellia Therapeutics

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics

Click here to get full coverage on INTELLIA THERAPEUTICS ($NTLA) Releases Q4 2025 Earnings - Quiver Quantitative

INTELLIA THERAPEUTICS ($NTLA) Releases Q4 2025 Earnings  Quiver Quantitative

INTELLIA THERAPEUTICS ($NTLA) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade - simplywall.st

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade  simplywall.st

Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade - simplywall.st

Click here to get full coverage on $NTLA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

$NTLA stock is down 10% today. Here's what we see in our data.  Quiver Quantitative

$NTLA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Intellia (NTLA) Soars 13% to Fresh High - Yahoo Finance

Intellia (NTLA) Soars 13% to Fresh High  Yahoo Finance

Intellia (NTLA) Soars 13% to Fresh High - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan

Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares  Stock Titan

Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan

Click here to get full coverage on Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? - Zacks Investment Research

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?  Zacks Investment Research

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? - Zacks Investment Research

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Yahoo Finance

Click here to get full coverage on Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums - Stock Titan

Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums  Stock Titan

Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums - Stock Titan

Click here to get full coverage on Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance

Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’  Yahoo Finance

Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance

Click here to get full coverage on Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Yahoo Finance

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?  Yahoo Finance

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Yahoo Finance

Click here to get full coverage on Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Yahoo Finance

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data  Yahoo Finance

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on $NTLA stock is down 7% today. Here's what we see in our data. - Quiver Quantitative

$NTLA stock is down 7% today. Here's what we see in our data.  Quiver Quantitative

$NTLA stock is down 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema  Intellia Therapeutics

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Click here to get full coverage on Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - Yahoo Finance

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress  Yahoo Finance

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program - Yahoo Finance

Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program  Yahoo Finance

Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - Intellia Therapeutics

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress  Intellia Therapeutics

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - Intellia Therapeutics

Click here to get full coverage on Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade - Yahoo Finance

Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade  Yahoo Finance

Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade - Yahoo Finance

Click here to get full coverage on $NTLA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative

$NTLA stock is up 20% today. Here's what we see in our data.  Quiver Quantitative

$NTLA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - Yahoo Finance

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know  Yahoo Finance

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Insider Purchase: Director at $NTLA Buys 100,000 Shares | NTLA Stock News - Quiver Quantitative

Insider Purchase: Director at $NTLA Buys 100,000 Shares | NTLA Stock News  Quiver Quantitative

Insider Purchase: Director at $NTLA Buys 100,000 Shares | NTLA Stock News - Quiver Quantitative

Click here to get full coverage on Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed? - Yahoo Finance

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?  Yahoo Finance

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics (NTLA): Evaluating Valuation After Phase 3 Gene-Editing Trial Halt and Share Price Drop - Yahoo Finance

Intellia Therapeutics (NTLA): Evaluating Valuation After Phase 3 Gene-Editing Trial Halt and Share Price Drop  Yahoo Finance

Intellia Therapeutics (NTLA): Evaluating Valuation After Phase 3 Gene-Editing Trial Halt and Share Price Drop - Yahoo Finance

Click here to get full coverage on Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? - Yahoo Finance

Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?  Yahoo Finance

Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? - Yahoo Finance

Click here to get full coverage on $NTLA stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

$NTLA stock is down 3% today. Here's what we see in our data.  Quiver Quantitative

$NTLA stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?  Yahoo Finance

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative

Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension  Quiver Quantitative

Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative

Click here to get full coverage on NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?  Zacks Investment Research

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research

Click here to get full coverage on Insider Sale: EVP of $NTLA Sells 31 Shares | NTLA Stock News - Quiver Quantitative

Insider Sale: EVP of $NTLA Sells 31 Shares | NTLA Stock News  Quiver Quantitative

Insider Sale: EVP of $NTLA Sells 31 Shares | NTLA Stock News - Quiver Quantitative

Click here to get full coverage on How to watch Intellia’s March investor talks at three healthcare conferences - Stock Titan

How to watch Intellia’s March investor talks at three healthcare conferences  Stock Titan

How to watch Intellia’s March investor talks at three healthcare conferences - Stock Titan

Click here to get full coverage on Why Did NTLA Stock Jump 10% Today? - Stocktwits

Why Did NTLA Stock Jump 10% Today?  Stocktwits

Why Did NTLA Stock Jump 10% Today? - Stocktwits

Click here to get full coverage on NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up - Yahoo Finance

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up  Yahoo Finance

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up - Yahoo Finance

Click here to get full coverage on Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know  Yahoo Finance

Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug  Seeking Alpha

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha

Click here to get full coverage on Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates  Yahoo Finance

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on $NTLA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

$NTLA stock is up 7% today. Here's what we see in our data.  Quiver Quantitative

$NTLA stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment - Yahoo Finance

Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment  Yahoo Finance

NTLA

Price Chart

Key Statistics

Technicals

About NTLA

Latest News

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) - The National Law Review

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility - simplywall.st

NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers